Leerink Partnrs Has Negative Outlook of enGene Q3 Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – Investment analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for enGene in a report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($0.33) per share for the quarter, down from their previous forecast of ($0.32). The consensus estimate for enGene’s current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for enGene’s Q4 2025 earnings at ($0.18) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($1.75) EPS.

A number of other research firms also recently issued reports on ENGN. Piper Sandler started coverage on shares of enGene in a research note on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 price target for the company. JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of enGene in a research report on Monday, December 23rd. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of enGene in a research report on Tuesday, March 11th. Morgan Stanley decreased their price objective on enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Finally, UBS Group lowered enGene from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $34.00 to $7.00 in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $24.13.

enGene Stock Up 1.0 %

Shares of NASDAQ ENGN opened at $4.00 on Friday. The firm has a fifty day simple moving average of $5.06 and a two-hundred day simple moving average of $6.71. The firm has a market capitalization of $203.91 million, a PE ratio of -6.90 and a beta of -0.38. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 12 month low of $3.50 and a 12 month high of $16.62.

Institutional Trading of enGene

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. increased its position in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after acquiring an additional 389,918 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in shares of enGene in the fourth quarter worth $69,000. Toronto Dominion Bank bought a new position in shares of enGene during the fourth quarter valued at $97,000. VR Adviser LLC boosted its position in shares of enGene by 41.5% during the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock valued at $33,559,000 after buying an additional 1,480,573 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its holdings in enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after buying an additional 2,080 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.